Sorrento Therapeutics Inc
LSE:0L85

Watchlist Manager
Sorrento Therapeutics Inc Logo
Sorrento Therapeutics Inc
LSE:0L85
Watchlist
Price: 0.015 USD -38.02% Market Closed
Market Cap: $1.7m

Operating Margin

-544.5%
Current
Declining
by 30.6%
vs 3-y average of -513.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-544.5%
=
Operating Income
$-350.1m
/
Revenue
$64.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-544.5%
=
Operating Income
$-350.1m
/
Revenue
$64.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Sorrento Therapeutics Inc
OTC:SRNE
706.8k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-544.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Sorrento Therapeutics Inc
Glance View

Market Cap
1.7m USD
Industry
Biotechnology

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.

0L85 Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-544.5%
=
Operating Income
$-350.1m
/
Revenue
$64.3m
What is Sorrento Therapeutics Inc's current Operating Margin?

The current Operating Margin for Sorrento Therapeutics Inc is -544.5%, which is below its 3-year median of -513.9%.

How has Operating Margin changed over time?

Over the last 3 years, Sorrento Therapeutics Inc’s Operating Margin has decreased from -498% to -544.5%. During this period, it reached a low of -758.8% on Dec 31, 2021 and a high of -494.9% on Mar 31, 2023.

Back to Top